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Abstract
Immune thrombocytopenic purpura (ITP), also known
as idiopathic thrombocytopenic purpura, is an acquired
immune-mediated disease of adults and children
characterized by a transient or persistent decrease of platelets
and, depending upon the degree of thrombocytopenia, an
increased risk of bleeding. The use of standard treatments
for acute myocardial infarction (AMI), such as antiplatelet
agents and anticoagulants, pose serious problems in
patients with ITP due to the potential higher risk of bleeding
complications. There are no current guidelines available
for management of ITP patients with AMI. In this brief
review of the limited available literature, we discuss the
proposed pathophysiological link between ITP and arterial
thrombosis and the challenging medical and interventional
treatment of these patients. (J Patient-Centered Res Rev.
2014;1(1):41-45.)
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Introduction
Immune (idiopathic) thrombocytopenic purpura (ITP), an
acquired immune-mediated disease of adults and children
characterized by a transient or persistent decrease of
platelets, poses an increased risk of bleeding among affected
patients.1,2 The additional risk varies according to the degree
of thrombocytopenia. ITP patients who also endure acute
myocardial infarction (AMI), are rarely encountered. The
standard treatments for AMI, including antiplatelet agents
and the necessity of the administration of anticoagulants
and antiplatelet agents during and following a percutaneous
coronary intervention (PCI) procedure, is the major
concern for this group of patients. Thrombolytic therapy is
contraindicated in ITP because of the high risk of bleeding.
There are no current guidelines for the management of AMI

Correspondence: Fengyi Shen, MD
c/o 1020 N. 12th Street, Suite 4180, Milwaukee, WI 53233
Email: fyshen99@yahoo.com
Reviews

in thrombocytopenic patients. In this report, several possible
etiologies for thrombosis in ITP are discussed in light of
a 58-year-old female with chronic ITP who developed
recurrent AMI secondary to thrombosis. This case, along
with the limited available literature, suggests that a modified
treatment strategy, carefully combining PCI with antiplatelet
and anticoagulant therapy, can be administered successfully
for AMI in ITP patients.

Illustrative Case
A 58-year-old female with a history of chronic ITP with
multiple exacerbations, complicated by diabetes mellitus and
hypertension secondary to long-term steroid use, presented
with shortness of breath and chest pain over 24 hours. The
patient was initially diagnosed with ITP in 1988 and had been
taking prednisone 5–10 mg daily nearly continuously. During
that time, she had experienced several ITP exacerbations
which were typified by gingivorrhagia and petechiae on her
legs (with extremely low platelet counts, once reaching a
nadir of 3 x 109/L). The flares were treated with rituximab, IV
immunoglobin, and/or high doses of prednisone. A splenectomy
had also been performed secondary to repetitive episodes of
thrombocytopenia. One week prior to this hospitalization, the
patient had a severe acute ITP exacerbation, with a platelet
count minimum of 9 x 109/L and was treated with a high
dose of prednisone, plus rituximab, for three days before
presentation. Laboratory data obtained on admission included
a platelet count of 100 x 109/L, an elevated troponin I of
6.6 µg/L and a CK-MB of 63. Admission vital signs were
stable. An EKG revealed ST segment elevations and small
Q-waves in leads I and aVL, associated with ST depressions
in the inferior leads (Fig. 1a). ST-elevation myocardial
infarction (STEMI) was diagnosed and the patient was
immediately referred to the cardiac catheterization laboratory.
Subsequent coronary angiography revealed a clot in the midleft anterior descending artery (LAD) which was deemed the
likely culprit lesion for her myocardial infarction (Fig. 2a).
Aspiration thrombectomy was performed with successful
restoration of brisk flow throughout the entire LAD. Chest
pain and ST-segment changes subsequently improved. There
was no lesion that required stenting, and all coronary arteries
were free of underlying atherosclerotic disease; intravenous
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Figure 1a and 1b. Electrocardiogram tracings recorded on the day of admission (a) and on the day of
recurrent MI (b).

(IV) heparin bolus (5,000 units), without further infusion, was
given during the procedure and eptifibatide was bolused at
180 mcg/kg followed by continuous infusion at 2 mcg/kg/min
for 12 hours. Aspirin 325 mg and clopidogrel 75 mg were
administered orally before and daily after the procedure.
Within 16 hours, the patient developed recurrent severe
chest pain associated with new ST-segment elevations in the
lateral and anterior leads (Fig. 1b), as well as progressive
cardiogenic shock. Repeat angiogram was pursued and
demonstrated a diffusely thrombosed LAD with heavy
clot burden and minimal flow distally (Fig. 3a). Extensive
aspiration thrombectomy was again attempted. Flow
improved in the proximal LAD, but there was only mild
improvement distally with some residual embolization
(Fig. 3b). Intracoronary adenosine was then given without
improvement in blood flow. During the PCI, eptifibatide and
heparin were reinitiated. This time the heparin infusion was
continued for 16 hours post procedure. After completion of
eptifibatide, the patient received a bivalirudin drip for three
days following the catherization. The patient was discharged
home in stable condition after 11 days of hospitalization
without bleeding or thrombocytopenic complications. Her
platelet count at discharge was 475 x 109/L. One month later,
she was readmitted for unstable angina without recurrent
coronary artery thrombosis detected on angiography.
She subsequently received an implantable cardioverter
defibrillator because of a persistent 25% cardiac ejection
fraction by echocardiography.
Considering her recurrent arterial thrombosis without
predisposing anatomical lesions, extensive coagulation tests
were performed including lupus anticoagulant, anticardiolipin
antibody, beta-2 glycoprotein antibodies, protein C, protein S,
homocysteine and factor VII. All tests were negative.
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Although ITP usually causes bleeding and is not considered
a prothrombotic state, it may be associated with increased
risk of thrombotic events including myocardial infarction,
ischemic stroke,3 and venous thrombosis. Thrombotic
complications have been reported to occur during or after
treatment when platelet counts begin to rise4,5 and even
during the severe to moderate thrombocytopenia phase.6
However, the reported incidence of myocardial infarction in
patients with chronic thrombocytopenia is low.7

Possible Etiology of Thrombosis in ITP
The mechanism of arterial thrombosis in ITP patients is still
unclear, but several hypotheses exist:
• One theory is that an antibody reaction shatters the
platelets and releases platelet microparticles (PMPs),
which are highly thrombogenic. PMPs may protect against
bleeding in thrombocytopenic states, but they may also
precipitate thrombosis. In this case, the synergistic action
of prothrombotic factors in ITP may override the protective
effect of thrombocytopenia.
• In ITP patients, platelets are larger, younger, and thus more
active. The treatment in ITP may cause the platelet count to
rise very rapidly.
• Some therapies can cause thrombotic complications,
including splenectomy. Splenectomy, in turn, may cause
portal vein thrombosis, pulmonary embolism and deep
vein thrombosis.8
• Steroid therapy is known to induce metabolic changes,
as well as a hypercoagulable state which may contribute
to the clinical scenario of thrombogenesis intravenous
immunoglobulin (IVIG). This can increase blood viscosity,
activating platelets or causing vasospasm.9
• Danazol is sometimes used in treating ITP patients and has
been noted to be associated with arterial thrombosis.10
Reviews
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Figure 2a and 2b. First selective left coronary angiogram showing thrombotic lesions in the LAD (a) and
angiographic result after thrombectomy with restored blood flow (b).
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Figure 3a and 3b. Second selective second left coronary angiogram showing diffusely thrombosed LAD with heavy clot burden (a) and angiographic result after re-thrombectomy with mild improvement of the blood flow (b).

• Another possible etiology of the thrombotic events in
ITP patients is that the autoantibodies in ITP directed
against antigens present on both platelets and endothelial
cells might induce endothelial damage, thereby causing
thrombus formation and embolic occlusion of the artery.6
• A considerable percentage of patients with ITP also have
antiphospholipid antibodies (aPL), which have been
Reviews

associated with thrombotic events in other patients. The
exact frequency and clinical significance of aPL in ITP
patients, however, is still controversial. In one study of
patients with newly diagnosed ITP and platelet counts
< 50 x 109/L, aPL were found in 26%, but their presence was
not associated with clinical manifestations of ITP.11 As noted,
the patient in our illustrative case was negative for aPL.
Aurora.org/Journal
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Challenging Treatment of AMI in ITP Patients
Management of AMI in ITP patients is still controversial.
Thrombolytic therapy for the treatment of AMI is
contraindicated in ITP patients due to the high risk of
bleeding diathesis.12 PCI is challenging, but it is considered
the most effective approach to treat these patients. The
necessity of stent implantation, as well as the administration
of anticoagulants and antiplatelets during and following
the procedure, is the major concern related to the PCI.
Performance of PCI in a patient with ITP presents a unique
situation in which platelet function needs to be inhibited
sufficiently to perform PCI safely, but not to the extent that
bleeding complications occur.13
We were able to find six cases reported in the literature of
primary PCI for AMI patients with ITP. Fuchi et al.14 reported
a 71-year-old ITP patient with AMI who underwent balloon
angioplasty. The patient developed LAD reinfarction and a
second primary PCI was performed, later complicated by a
large hematoma at the femoral arterial access site. The patient
received IVIG and methylprednisolone, which resulted in
bleeding cessation. Gracia et al.15 reported an ITP patient
who underwent PCI for total LAD occlusion. He received
heparin prophylaxis and combined antiplatelet therapy.
Fong et al.16 reported a case of acute coronary syndrome
in a 71-year-old female with ITP. The patient received
IVIG premedication and underwent PCI through the radial
artery. The patient tolerated seven weeks of clopidogrel
treatment without complications. Caputo et al.17 reported a
62-year-old refractory ITP patient with a platelet count of
3 x 109/L who received stent placement in the LAD. This
was followed by four weeks of aspirin and two weeks of
clopidogrel without bleeding complications. Stouffer et al.13
reported a 77-year-old man with ITP and platelet count of
70 x 109/L who underwent two separate cardiac catherization
procedures due to obstructive disease of the left circumflex
and restenosis at the site of the previous lesion. Eptifibatide,
clopidogrel and an intracoronary stent were administered
without complications. Another case was reported by Kim
et al.18 regarding a 47-year-old woman with chronic ITP who
was diagnosed with inferior AMI and treated successfully by
primary PCI. Heparin was given during the PCI and aspirin
and clopidogrel were instituted after the procedure.
In our illustrative case, the patient had no atheromatous
process detected in her coronary arteries, therefore, stent
placement was not warranted. For ITP patients with underlying
coronary artery disease, available data suggests that baremetal stents may be preferrable to drug-eluting stents,
because of the shorter duration of dual antiplatelet therapy
44
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(aspirin plus clopidogrel) required. However, there is no
direct data comparing the safety of the two stent types in ITP.19
Heparinoids, including unfractionated heparin (UFH) and
fondaparinux, have been used successfully during PCI
in patients with ITP. There is no optimal dose of heparin
suggested in such patients. However, the standard weightadjusted dose, or smaller dose of heparin plus IVIG
therapy during the thrombocytopenic phase,18 has been
recommended. Our patient was given heparin during the
first PCI, but the infusion was not continued after the first
procedure secondary to bleeding concerns. She experienced
reinfarction within 24 hours, which raises the question of
whether a continuous infusion of heparin might have been
able to prevent this. Neskovic et al. suggested fondaparinux
can be used with a half dose of UFH, so as to minimize the
risk of heparin-induced thrombocytopenia (HIT). In addition,
fondaparinux, unlike UFH and low molecular weight heparin,
has no effect on platelet function and may thus decrease the
risk of serious bleeding in thrombocytopenic patients.20 The
addition of UFH to fondaparinux is recommended due to an
increased risk of catheter thrombosis that has been reported
when using fondaparinux alone during PCI.
The direct thrombin inhibitors are considered to be a valuable
option for patients with ITP undergoing PCI. Bivalirudin is
the only agent approved to use for anticoagulation during
PCI in patients with HIT, although other direct thrombin
inhibitors (lepirudin and argatroban) have also been used.21
The administration of glycoprotein IIb/IIIa inhibitors, such
as eptifibatide, are indicated during and following PCI, but
they have been reported to produce severe thrombocytopenia
in some ITP patients while they were well-tolerated in
other reports.14,22 Based on the above observations, we
switched from eptifibatide to bivalirudin for our patient.
Neither eptifibatide nor bivalirudin led to any bleeding or
thrombocytopenic complications in our case.
Moreover, it is recommended that dual antiplatelet therapy
with aspirin and clopidogrel should be prescribed for a
shorter period of time to allow stent endothelialization. Our
patient was given aspirin and clopidogrel before and after
the procedure even without stent implantation.

Conclusion
The mechanism of thromboembolism in ITP patients is still
unclear, but several hypotheses exist. Thrombolytic therapy
is contraindicated in AMI in ITP patients. Clinicians caring
for patients with AMI in the face of ITP should consider
that primary PCI may be an effective and safe therapeutic
Reviews

treatment. Antiplatelet and anticoagulation therapy can be
used cautiously during and after PCI without bleeding or
thrombocytopenic complications. Also, dual antiplatelet
therapy (aspirin plus clopidogrel) can be well-tolerated in
these patients if thrombocytopenia is not severe.
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